Skip to main content

Talk Bio

Search This Blog

KOL Views Q&A: Prostate cancer at ASCO 2026—detailed looks at upstream data for J&J's Erleada, Pfizer's Talzenna

on June 03, 2026

Get link
Facebook
X
Pinterest
Email
Other Apps

PROTEUS Phase 3 trial for Erleada plus hormone therapy before and after prostatectomy shows 9-fold higher rate of near‑complete pathological response and 20% lower risk of metastasis or death in high‑risk localized prostate cancer.

TALAPRO‑3 Phase 3 trial for Talzenna plus Xtandi vs Xtandi plus placebo in HRR‑altered mCSPC shows 52% reduction in rPFS risk (BRCAm 63%, non‑BRCAm 43%) and a favorable OS trend; TALZENNA plus XTANDI is already approved in mCRPC in the US and EU, and diagnostics are newly cleared to support this indication.

Sources:

ASCO '26: Bispecifics vs. ADCs, a 'RAS' revolution and a step ...

ASCO 2026: Talzenna and Xtandi combo has first-line promise in ...

ASCO26: Big win for Erleada in perioperative prostate cancer

TALZENNA Plus XTANDI Improves Radiographic Progression-Free ...

Janssen Data at ASCO GU Demonstrate Longstanding Leadership ...

Johnson & Johnson's Phase 3 prostate cancer study shows ...

ASCO: Pfizer scores in lung, colorectal and prostate cancer but key ...

Study: Promising early results for treating metastatic prostate cancer

TALZENNA Plus XTANDI Significantly Improves Radiographic ...

ASCO GU 2022 - ERLEADA ® Real-World Study in Metastatic ...

[PDF] ERLEADA® (apalutamide) tablets, for oral use - accessdata.fda.gov

Pfizer's TALZENNA® in Combination with XTANDI® Prolongs ...

[PDF] Johnson & Johnson ushers in the next wave of innovation in cancer ...

Erleada upstream data ASCO Format (qualifier value) KOL Localized Malignant neoplasm of prostate mCSPC Poly(ADP-ribose) Polymerase Inhibitors PROTEUS trial Talzenna Talzenna upstream data ASCO upstream data View

Get link
Facebook
X
Pinterest
Email
Other Apps

Popular Posts

KOL Bulletin: Brilaroxazine's Potential Differentiation on EPS Over Risperidone in Schizophrenia

A leading US KOL states that brilaroxazine shows placebo-like extrapyramidal symptoms (EPS) at week 4, potentially differentiating it from risperidone which cannot achieve this 1 . Reviva plans to initiate the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia in H1 2026 following FDA recommendation for additional efficacy and safety data 2 . Brilaroxazine demonstrates broad-spectrum efficacy across schizophrenia symptom domains, including negative symptoms, with a well-tolerated safety profile in over 900 subjects 2 4 . Phase 3 RECOVER trial data shows low EPS and akathisia, mild weight gain (1.52 kg pooled), reductions in prolactin levels, and improvements in sexual function over 1 year 4 . New publication highlights speech latency as an objective vocal biomarker for brilaroxazine's effect on negative symptoms, reinforcing efficacy 3 5 . Sources: 1. https://firstwordhealthtech.com 2. https://www.biospace.com/press-releases/reviva-announces-regulatory-update-...

Pfizer's Monthly GLP-1 Data from VESPER-3: Competitive Weight Loss Validates $10B Metsera Acquisition

Pfizer's Phase 2b VESPER-3 trial of ultra-long-acting GLP-1 RA PF-08653944 (MET-097i) achieved up to 12.3% placebo-adjusted weight loss at 28 weeks with monthly maintenance dosing after initial weekly titration 1 3 4 . Weight loss continued robustly post-switch to monthly dosing with no plateau observed at week 28, supporting Phase 3 advancement including higher 9.6 mg dose 1 3 . Data described as competitive with rivals (9-13% at week 28), validating Pfizer's $10B Metsera acquisition, with 10 Phase 3 trials planned for 2026 1 3 2 . Tolerability profile favorable with mostly mild/moderate GI events; full VESPER-3 data to be presented June 2026 1 3 . Analysts view results as encouraging but note questions on placebo benefits, discontinuations, and comparison to prior weekly data 3 5 . Sources: 1. https://www.pfizer.com/news/press-release/press-release-detail/pfizers-ultra-long-acting-injectable-glp-1-ra-shows-robust 2. https://www.pharmaceutical-technology.com/anal...

Ultragenyx Resubmits BLA for UX111 Gene Therapy with New Long-Term Data for Sanfilippo Syndrome Type A

Ultragenyx resubmitted its Biologics License Application (BLA) to the FDA for UX111, an AAV9 gene therapy for Sanfilippo syndrome type A (MPS IIIA), including long-term clinical data on neurologic, biomarker, and safety improvements. 1 2 3 4 5 The resubmission addresses a Complete Response Letter from July 2025 related to manufacturing (CMC) observations and adds durable biomarker reductions, such as CSF heparan sulfate, with favorable safety profile. 2 4 5 FDA's six-month priority review has begun; PDUFA action date expected in Q3 2026. 2 4 5 If approved, UX111 would be the first therapy for this fatal pediatric neurodegenerative disorder. 1 3 4 5 New long-term data announced February 3, 2026, shows substantial biomarker improvements and functional benefits vs. natural history, consistent across age and severity. 2 Sources: 1. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/ultragenyx-bla-resubmission-puts-ux111-and-ra...

Powered by Blogger

X-Data LLC